KRAS and pancreatic intraductal papillary-mucinous neoplasm: Based on these findings, we suggest that close monitoring of lesion progression and more aggressive intervention such as surgery and novel therapeutics should be applied to IPMN with concomitant mutations of KRAS and RNF43.